Yahoo Web Search

Search results

1. • 

     UC San Diego Health First in Region to Provide Nov | Newswise

     Newswise· 5 days ago

     UC San Diego Health is the first hospital system in the region to offer a new immunotherapy...

2. • 

     Hedge Funds are Bullish on This Gene Therapy Stock

     Insider Monkey via Yahoo Finance· 6 days ago

     We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss Gilead Sciences, Inc. (NASDAQ:GILD), which is...

3. • 

     ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor

     BioPharma Dive via Yahoo Finance· 6 days ago

     AstraZeneca’s therapy could see wider use after ASCO data. Elsewhere, Caribou sought to explain an...

4. • 

     AbbVie treats first subject in Phase III multiple myeloma drug trial

     Clinical Trials Arena via Yahoo Finance· 3 days ago

     AbbVie has treated the first subject in the Phase III CERVINO clinical trial of its investigational...

5. • Small Business - The Brewton Standard | The Brewton Standard

     The Brewton Standard· 3 days ago

     WARREN, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic

6. • 

     Dr. Jeff Hersh addresses cause, effects and complications of Graft vs Host Disease

     Gannett via AOL· 1 day ago

     Graft vs Host Disease occurs when white blood cells produced by donated stem cells identify the...

7. • Small Business - Salisbury Post | Salisbury Post

     The Salisbury Post· 5 days ago

     CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO PR Newswire SHANGHAI, June 4, 2024 SHANGHAI, June 4, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative

8. • BlueSphere Bio's huge week with FDA approval for dosing and National Cancer Institute agreement -...

     The Business Journals· 2 days ago

     BlueSphere Bio, a UPMC Enterprises spinout and Pittsburgh-based drug development company, logged a big week in its development with a clearance from the U.S. Food and Drug Administration and ...

9. • 

     Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval

     Zacks via Yahoo Finance· 2 days ago

     AbbVie Starts Phase III Multiple Myeloma Study on BCMA Therapy, ABBV-383: AbbVie announced that it...

10. • CARVYKTI® (ciltacabtagene autoleucel) significantly improved progression-free survival and deepened...

      Valley City Times Record· 6 days ago

      Johnson & Johnson announced today results from a subgroup analysis of the Phase 3 CARTITUDE-4 study. Data from the CARTITUDE-4 study supported the recent U.S. FDA approval of CARVYKTI®, the ...